Castle Biosciences (CSTL) Research & Development (2018 - 2026)

Castle Biosciences has reported Research & Development for 9 years, with the latest figure at $14.5 million in Q2 2026.

• Quarterly Research & Development rose 13.73% year-over-year to $14.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $55.4 million (up 12.08% YoY) and the FY2025 annual result came in at $51.8 million, changed 0.37% from the prior year.
• Research & Development climbed to $14.5 million in Q2 2026 per CSTL's latest filing, from $14.4 million in the prior quarter.
• Over five years, Research & Development peaked at $14.5 million in Q2 2026 and troughed at $10.8 million in Q1 2022.
• A 5-year average of $12.9 million and a median of $12.9 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development surged 82.14% in 2022, then fell 9.54% in 2025.
• Over 5 years, Research & Development stood at $11.3 million in 2022, then advanced by 14.9% to $13.0 million in 2023, then declined by 9.4% to $11.8 million in 2024, then grew by 14.8% to $13.5 million in 2025, then climbed by 7.61% to $14.5 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $14.5 million, $14.4 million, and $13.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.